Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Sequence Type 11 Due to a Mutation in Plasmid-Borne bla_kpc-2 to bla_kpc-33, in Henan, China

References

• Kim D, Ahn JY, Lee CH, et al. Increasing resistance to extended-spectrum cephalosporins, fluoroquinolone, and carbapenem in gram-negative bacilli and the emergence of carbapenem non-susceptibility in Klebsiella pneumoniae: analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) data from 2013 to 2015. Ann Lab Med. 2017;37(3):231–239. doi:10.3343/alm.2017.37.3.23128224769
   PubMed Web of Science ®Google Scholar
• Plazak ME, Tamma PD, Heil EL. The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC)-producing bacteria. Expert Opin Pharmacother. 2018;19(18):2019–2031. doi:10.1080/14656566.2018.153835430346216
   PubMed Web of Science ®Google Scholar
• Zhang R, Liu L, Zhou H, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98–106. doi:10.1016/j.ebiom.2017.04.03228479289
   PubMed Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-328356109
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328. doi:10.1128/AAC.02166-1324514083
   PubMed Web of Science ®Google Scholar
• Hu F, Guo Y, Zhu D, et al. CHINET surveillance of bacterial resistance across tertiary hospitals in 2019. Chin J Infect Chemother. 2020;20(3):233–243.
   Google Scholar
• US FDA. Avycaz (ceftazidime and avibactam) for injection, for intravenous use: US prescribing information; 2018. Available from: https://www.accessdata.fda.gov. Accessed 316, 2018.
   Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x29671219
   PubMed Web of Science ®Google Scholar
• Lahiri SD, Bradford PA, Nichols WW, Alm RA. Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations. J Antimicrob Chemother. 2016;71(10):2848–2855. doi:10.1093/jac/dkw24827402011
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. doi:10.1093/cid/ciw63627624958
   PubMed Web of Science ®Google Scholar
• Giddins MJ, Macesic N, Annavajhala MK, et al. Successive emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in blaKPC-2-harboring Klebsiella pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62(3):e02101–17. doi:10.1128/AAC.02101-1729263067
   PubMed Web of Science ®Google Scholar
• Shi Q, Yin D, Han R, et al. Emergence and recovery of ceftazidime-avibactam resistance in blaKPC-33-harboring Klebsiella pneumoniae sequence type 11 isolates in China. Clin Infect Dis. 2020;71(Supplement_4):S436–S439. doi:10.1093/cid/ciaa152133367577
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 2019:M100–S29.
   Google Scholar
• Tsakris A, Poulou A, Pournaras S, et al. A simple phenotypic method for the differentiation of metallo beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother. 2010;65(8):1664–1671. doi:10.1093/jac/dkq21020542902
   PubMed Web of Science ®Google Scholar
• Schmieder R, Edwards R. Quality control and preprocessing of metagenomic datasets. Bioinformatics. 2011;27(6):863–864. doi:10.1093/bioinformatics/btr02621278185
   PubMed Web of Science ®Google Scholar
• Nurk S, Bankevich A, Antipov D, et al. Assembling single-cell genomes and mini-metagenomes from chimeric MDA products. J Comput Biol. 2013;20(10):714–737. doi:10.1089/cmb.2013.008424093227
   PubMed Web of Science ®Google Scholar
• Bortolaia V, Kaas RS, Ruppe E, et al. ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020;75(12):dkaa345. doi:10.1093/jac/dkaa345
   Web of Science ®Google Scholar
• Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–1760. doi:10.1093/bioinformatics/btp32419451168
   PubMed Web of Science ®Google Scholar
• Li H, Handsaker B, Wysoker A, et al. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–2079. doi:10.1093/bioinformatics/btp35219505943
   PubMed Web of Science ®Google Scholar
• Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097–16. doi:10.1128/AAC.02097-1628031201
   PubMed Web of Science ®Google Scholar
• Bianco G, Boattini M, Iannaccone M, Cavallo R, Costa C. Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay. J Antimicrob Chemother. 2020;75(10):3075–3076. doi:10.1093/jac/dkaa28332676660
   PubMed Web of Science ®Google Scholar
• Bianco G, Boattini M, van Asten SAV, et al. RESIST-5 O.O.K.N.V. and NG-Test Carba 5 assays for the rapid detection of carbapenemase-producing Enterobacterales from positive blood cultures: a comparative study. J Hosp Infect. 2020;105(2):162–166. doi:10.1016/j.jhin.2020.03.02232304724
   PubMed Web of Science ®Google Scholar
• Oueslati S, Iorga BI, Tlili L, et al. Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. J Antimicrob Chemother. 2019;74(8):2239–2246. doi:10.1093/jac/dkz20931127297
   PubMed Web of Science ®Google Scholar
• Levitt PS, Papp-Wallace KM, Taracila MA, et al. Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis. J Biol Chem. 2012;287(38):31783–31793. doi:10.1074/jbc.M112.34854022843686
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. In vitro selection of meropenem resistance among ceftazidime-avibactam-resistant, meropenem-susceptible Klebsiella pneumoniae isolates with variant KPC-3 carbapenemases. Antimicrob Agents Chemother. 2017;61(5):e00079–17. doi:10.1128/AAC.00079-1728242667
   PubMed Web of Science ®Google Scholar
• Gaibani P, Campoli C, Lewis RE, et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018;73(6):1525–1529. doi:10.1093/jac/dky08229566151
   PubMed Web of Science ®Google Scholar
• Compain F, Arthur M. Impaired inhibition by avibactam and resistance to the ceftazidime-avibactam combination due to the D179Y substitution in the KPC-2 β-lactamase. Antimicrob Agents Chemother. 2017;61(7):e00451–17. doi:10.1128/AAC.00451-1728461318
   PubMed Web of Science ®Google Scholar
• Hemarajata P, Humphries RM. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2. J Antimicrob Chemother. 2019;74(5):1241–1243. doi:10.1093/jac/dkz02630753572
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497–17. doi:10.1128/AAC.02497-1729507064
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lewis RE, Volpe SL, et al. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1–3. doi:10.1016/j.ijid.2017.09.01728951106
   PubMed Web of Science ®Google Scholar
• Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH. Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother. 2017;61(5):e02534–16. doi:10.1128/AAC.02534-1628223379
   PubMed Web of Science ®Google Scholar